item management s discussion and analysis of financial condition and results of operations overview since commencement of operations in  the company has been engaged primarily in the research and development of pharmaceutical products and systems to enable the body s immune system to better tolerate the transplantation of foreign cells  tissues and organs 
the major sources of the company s working capital have been the proceeds from sales of equity securities  sponsored research funding and license fees and capital lease financings 
the company has not generated any revenues from the sale of products to date  and does not expect to receive any product revenues for several years  if ever 
the company will be required to conduct significant additional research  development  testing and regulatory compliance activities that  together with general and administrative expenses  are expected to result in significant and increasing operating losses for at least the next several years 
in  and as amended and restated in september  the company and novartis entered into a collaboration agreement for the development and commercialization of xenotransplantation products utilizing gene transduction 
under the agreement  novartis committed research funding and license fees through march of million  all of which had been received as of december  novartis has also agreed to fund certain development and premarketing costs and products which may be developed as a result of the collaboration  portions of which  under certain circumstances  may be repayable from the company s operating profits from sales of any such products 
in october  the company and novartis expanded their relationship by entering into a collaboration and license agreement to develop and commercialize xenotransplantation products utilizing the company s proprietary mixed bone marrow chimerism technology 
under the agreement  the company may receive from novartis research funding  license fees  and milestone payments of up to million assuming the agreement continues for its full term and certain research objectives are met 
as of december   research funding of million  license fees of million and milestone payments of million had been received 
in addition to research funding  novartis will also fund certain development and premarketing costs of such products  portions of which may be repayable under certain circumstances 
in october  the company and medimmune entered into a collaborative research agreement for the development of products to treat and prevent organ rejection 
medimmune paid the company a million license fee at the time of execution of the agreement  and agreed to fund and assume responsibility for clinical testing and commercialization of bti and other related products 
medimmune has provided million of non refundable research support and has agreed to make milestone payments which could total up to an additional million 
any milestone payments which are received are repayable from royalties on such products 
results of operations years ended december  and revenues increased to million in from million in the increase in revenues was primarily due to million in sponsored research  milestone payments and license revenue from the novartis agreements in  compared to million in sponsored research and license revenue from novartis during interest income decreased to million in compared to million in the decrease was due to lower average cash balances available for investment during research and development expenses increased to million in from million in this increase was primarily due to additional external research support combined with increases in research and development staff and associated increases in supplies and support services 
general and administrative expenses decreased slightly to million in from million in this decrease was primarily due to decreased outside professional services rendered in connection with market research and business development 
interest expense increased to  in from  in this increase was primarily due to borrowings under a term note in as a result of the above factors  the company incurred a net loss for of million compared to a net loss of million for years ended december  and revenues decreased to million in from million in the decrease in revenues was primarily due to million in sponsored research and license revenue from the novartis agreements in  compared to million in sponsored research and license revenue from novartis during additionally  interest income decreased to million in compared to million in the increase in interest income was due to lower average cash balances available for investment during research and development expenses increased to million in from million in this increase was primarily due to additional external research support combined with increases in research and development staff and associated increases in supplies and support services 
general and administrative expenses decreased to million in from million in this decrease was primarily due to decreased outside professional services rendered in connection with market research and development 
interest expense decreased to  in from  in this decrease was primarily due to decreasing balances on existing obligations under capital leases 
as a result of the above factors  the company incurred a net loss for of million compared to a net loss of million for liquidity and capital resources since its inception  the company s operations have been funded principally through the net proceeds of an aggregate of million from sales of equity securities 
the company has also received million from research and development and collaboration agreements with novartis  million from an alliance agreement with medimmune and million in equipment financing 
the proceeds of the sales of equity securities  notes payable and capital leases and cash generated from the corporate collaborations with novartis and medimmune have been used to fund operating losses of approximately million and the investment of approximately million in equipment and leasehold improvements through december  the company extended and increased its term note with a bank from  to million for certain equipment and fixtures borrowing 
there were  in borrowings outstanding under this term note at december  the company had no significant commitments as of december  for capital expenditures 
on december   the company issued and sold to a group of investors an aggregate of  shares of its common sock  
par value per share  at a purchase price of per share for net proceeds to the company of approximately million 
on february   the company issued and sold to a group of investors an aggregate of  shares of its common stock  
par value per share  at a purchase price of per share  for net proceeds to the company of approximately million 
the company has entered into sponsored research and consulting agreements with certain hospitals  academic institutions and consultants  requiring periodic payments by the company 
aggregate minimum funding obligations under these agreements  which include certain cancellation provisions  total approximately million  which includes approximately million in the company had cash and cash equivalents and investments of million as of december  the company anticipates that its existing funds should be sufficient to fund its operating and capital requirements as currently planned through however  the company s cash requirements may vary materially from those now planned due to many factors  including  but not limited to  the progress of the company s research and development programs  the scope and results of preclinical and clinical testing  changes in existing and potential relationships with corporate collaborators  the time and cost in obtaining regulatory approvals  the costs involved in obtaining and enforcing patents  proprietary rights and any necessary licenses  the ability of the company to establish development and commercialization capacities or relationships  the costs of manufacturing and other factors 
the company expects to incur substantial additional costs  including costs related to research and development activities  preclinical studies  clinical trials  obtaining regulatory approvals  manufacturing and the expansion of its facilities 
the company will need to raise substantial additional funds  through additional financings including public or private equity offerings and collaborative arrangements with corporate partners 
there can be no assurance that funds will be available on terms acceptable to the company  if at all 
if adequate funds are not available  the company may be required to delay  scale back or eliminate certain of its product development programs or to license to others the right to commercialize products or technologies that the company would otherwise seek to develop and commercialize itself  any of which would have a material and adverse effect on the company 
year readiness historically  certain computer programs have been written using two digits rather than four digits  to define the applicable year 
this could lead  in many cases  to a computer s recognition of a date using as rather than the year this phenomenon could result in significant computer system failures or miscalculations  and is generally referred to as the year problem or issue 
at december   the company had completed an inventory of its financial and management operating systems and updated or replaced any programs that were not year compliant 
the company estimates that the cost to remediate its financial and management operating systems and embedded chips in its facilities or equipment was less than  including capital costs for new computers and related equipment 
this amount does not include costs for computer software developed in order to provide or improve functionality 
the company has also interviewed third parties  vendors and suppliers of the company to determine their exposure to year issues  their anticipated risks and responses to those risks 
the company completed this process and no material risks were identified 
item a 
quantitative and qualitative disclosures about market risk s the company owns financial instruments that are sensitive to market risks as part of its investment portfolio 
the investment portfolio is used to preserve the company s capital until it is required to fund operations  including the company s research and development activities 
all of these market risk sensitive instruments are classified as held to maturity and are not held for trading purposes 
the company does not own derivative financial instruments in its investment portfolio 
the investment portfolio contains instruments that are subject to the risk of a decline in interest rates 
interest rate risk the company s investment portfolio includes investment grade debt instruments 
these bonds are subject to interest rate risk  and could decline in value if interest rates fluctuate 
due to the short duration and conservative nature of these instruments  the company does not believe that it has a material exposure to interest rate risk 

